These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31602823)

  • 1. Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.
    Anderson CF; Grimmett ME; Domalewski CJ; Cui H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1586. PubMed ID: 31602823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges.
    Haque S; Whittaker MR; McIntosh MP; Pouton CW; Kaminskas LM
    Nanomedicine; 2016 Aug; 12(6):1703-24. PubMed ID: 27033834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine in pulmonary delivery.
    Mansour HM; Rhee YS; Wu X
    Int J Nanomedicine; 2009; 4():299-319. PubMed ID: 20054434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases.
    Yong J; Shu H; Zhang X; Yang K; Luo G; Yu L; Li J; Huang H
    Int J Nanomedicine; 2024; 19():1723-1748. PubMed ID: 38414528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalable liposomes for treating lung diseases: clinical development and challenges.
    Ponkshe P; Feng S; Tan C
    Biomed Mater; 2021 Jul; 16(5):. PubMed ID: 34134097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.
    Willis L; Hayes D; Mansour HM
    Lung; 2012 Jun; 190(3):251-62. PubMed ID: 22274758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review.
    Feng X; Shi Y; Zhang Y; Lei F; Ren R; Tang X
    Int J Nanomedicine; 2024; 19():1509-1538. PubMed ID: 38384321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates.
    Abdelaziz HM; Gaber M; Abd-Elwakil MM; Mabrouk MT; Elgohary MM; Kamel NM; Kabary DM; Freag MS; Samaha MW; Mortada SM; Elkhodairy KA; Fang JY; Elzoghby AO
    J Control Release; 2018 Jan; 269():374-392. PubMed ID: 29180168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell targeted pulmonary siRNA delivery for the treatment of asthma.
    Keil TWM; Baldassi D; Merkel OM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1634. PubMed ID: 32267622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotechnology approaches for inhalation treatment of lung diseases.
    Kuzmov A; Minko T
    J Control Release; 2015 Dec; 219():500-518. PubMed ID: 26297206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical nanoparticles for next generation drug delivery to the lungs.
    van Rijt SH; Bein T; Meiners S
    Eur Respir J; 2014 Sep; 44(3):765-74. PubMed ID: 24791828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine and drug delivery systems in cancer and regenerative medicine.
    Garbayo E; Pascual-Gil S; Rodríguez-Nogales C; Saludas L; Estella-Hermoso de Mendoza A; Blanco-Prieto MJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1637. PubMed ID: 32351045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines: Impactful Approaches for Targeting Pulmonary Diseases.
    Dhoundiyal S; Alam MA; Kaur A; Sharma S
    Pharm Nanotechnol; 2023 May; ():. PubMed ID: 37231722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases.
    Newman SP
    Adv Drug Deliv Rev; 2018 Aug; 133():5-18. PubMed ID: 29653129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicine as an innovative therapeutic strategy for pediatric lung diseases.
    Tian Y; Chen J; Zahtabi F; Keijzer R; Xing M
    Pediatr Pulmonol; 2013 Nov; 48(11):1098-111. PubMed ID: 23997035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.
    Shen AM; Minko T
    J Control Release; 2020 Oct; 326():222-244. PubMed ID: 32681948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy.
    Jin Z; Gao Q; Wu K; Ouyang J; Guo W; Liang XJ
    Adv Drug Deliv Rev; 2023 Nov; 202():115111. PubMed ID: 37820982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.
    Zhang XQ; Xu X; Bertrand N; Pridgen E; Swami A; Farokhzad OC
    Adv Drug Deliv Rev; 2012 Oct; 64(13):1363-84. PubMed ID: 22917779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis.
    Chae J; Choi Y; Tanaka M; Choi J
    J Biosci Bioeng; 2021 Dec; 132(6):543-551. PubMed ID: 34538591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial nanomedicine for the treatment of pulmonary disease.
    Brenner JS; Greineder C; Shuvaev V; Muzykantov V
    Expert Opin Drug Deliv; 2015 Feb; 12(2):239-61. PubMed ID: 25394760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.